Cancer trials underrepresent minorities and elderly, Mayo Clinic says

pharmafile | September 26, 2017 | News story | Manufacturing and Production, Research and Development clinical trials, pharma, pharmaceutical 

New research conducted by the Mayo Clinic in Minnesota has found participant groups for clinical trials in cancer underrepresent ethnic minorities and elderly patients, based on an analysis of enrolment data from from 2003-2016 – a total of 55,689 participants.  

Of this total group, the findings showed that 83% were white, 6% were African-American, 5.3% were Asian, 2.6% were Hispanic and 2.4% were identified as other.

Compared to the period immediately before, researchers found that this discrepancy is even more pronounced. Historical data from 1996 to 2002 showed that African-Americans and Hispanic patients made up 9.2% and 3.1% respectively during this time, showing that representation in these areas has declined.

On top of this, the data showed that patients older than 65 only accounted for 36% of total clinical trial participants.

The researchers gave a few reasons for these findings, including the increasing use of genetic information and cultural biases which could be a factor causing minority groups to be less likely to enrol in clinical trials.

“Clinical trials are crucial in studying the effectiveness of new drugs and ultimately bringing them to the market to benefit patients,” Dr. Narjust Duma, a haematology/oncology fellow at the Mayo Clinic. “However, many clinical trials lack appropriate representation of certain patient populations. As a result, the findings of a clinical trial might not be generalisable to all patients.

“This is leading to significant advances; however, it is vastly more expensive to run these trials, often leaving a limited budget to recruit patients or do outreach to the elderly or minorities,” she continued. “Also, this type of testing can only be conducted at the major cancer centres. The midsized, regional hospitals are excluded because they don’t have the capacity and, sadly, this leaves us farther away from these populations.”

Matt Fellows

Related Content


BioInvent and Transgene announce positive phase 1a solid tumour trial data

Sweden-based BioInvent and French Transgene, both biotech companies, have reported positive phase 1a data from …

PureTech Health’s Founded Entity Akili announces positive data from adult ADHD trial

Clinical-stage biotherapeutics company PureTech Health has reported that its Founded Entity Akili, a digital medicine …

Vicore announces initiation of proof-of-concept study for endothelial dysfunction treatments

Vicore Pharma Holding AB has announced that it has dosed the first patient with C21 …

Latest content